Form 4: Adverum Director's Options Cancelled Post-Eli Lilly Merger

Adverum Biotechnologies director Scott M Whitcup's stock options were cancelled following the acquisition by Eli Lilly and Company, with some receiving cash and CVRs, and others cancelled for no consideration.

Summary

• Adverum Biotechnologies, Inc. has been acquired by Eli Lilly and Company, with the merger becoming effective on December 9, 2025.
• The acquisition involved a tender offer where tendering stockholders received $3.56 per share in cash and one non-tradable contingent value right (CVR).
• Each CVR represents the contractual right to receive up to two contingent cash payments totaling up to an aggregate of $8.91 per CVR, contingent upon the achievement of specified milestones.
• Following the merger, Adverum Biotechnologies, Inc. continues as the surviving entity and a wholly-owned subsidiary of Eli Lilly and Company.
• Director Scott M Whitcup's stock options were treated according to the merger agreement.
• Out-of-the-money options (exercise price equal to or greater than the $3.56 cash consideration) were fully vested prior to the effective time and then cancelled for no consideration.
• Cash-out options (exercise price less than the $3.56 cash consideration) were cancelled in exchange for a cash payment equal to the difference between the cash consideration and the exercise price, multiplied by the number of shares, plus one CVR for each share subject to the option.

Sentiment

Score: 6

Explanation: The filing reports the outcome of a completed merger and the treatment of insider stock options. While some options were cancelled for no consideration, others were cashed out for a combination of cash and CVRs, which is a standard outcome in such transactions. The overall sentiment is neutral to slightly positive for the reporting person due to the cash and CVRs received for in-the-money options, balanced by the cancellation of out-of-the-money options.

Positives

• Shareholders who tendered their shares received a cash consideration of $3.56 per share, providing immediate liquidity.
• Tendering shareholders also received one Contingent Value Right (CVR) per share, offering potential future cash payments of up to $8.91 per CVR upon milestone achievement.
• Holders of 'Cash-Out Stock Options' (those with an exercise price less than $3.56) received a cash payment and CVRs for their options, providing a financial benefit from the merger.

Negatives

• Holders of 'Out-of-the-Money Options' (those with an exercise price equal to or greater than the $3.56 cash consideration) had their options cancelled for no consideration.
• Specifically, Scott M Whitcup's options for 6,000 shares at $116.2, 3,000 shares at $256.4, 4,000 shares at $37, 4,000 shares at $9.9, 4,000 shares at $15.6, and 10,520 shares at $7.32 were cancelled for no value.

Risks

• The contingent value rights (CVRs) are non-tradable and their value is dependent on the achievement of specified milestones, meaning there is no guarantee of receiving the full potential payment of up to $8.91 per CVR.

Future Outlook

Adverum Biotechnologies, Inc. will continue its operations as a wholly-owned subsidiary of Eli Lilly and Company. Future contingent cash payments to CVR holders are dependent on the achievement of specific milestones outlined in the CVR Agreement.

Industry Context

This acquisition reflects ongoing consolidation within the biotechnology and pharmaceutical sectors, where larger pharmaceutical companies acquire smaller biotech firms to expand their pipelines and therapeutic areas. The use of contingent value rights (CVRs) is a common mechanism in such deals to bridge valuation gaps and share future development risks and rewards.

Corporate Governance

Related Party Transactions

• The entire transaction, including the tender offer and subsequent merger, constitutes a related party transaction between Adverum Biotechnologies, Inc. and Eli Lilly and Company (Parent) and its direct wholly-owned subsidiary, Flying Tigers Acquisition Corporation (Purchaser).

Stakeholder Impact

• Shareholders: Received $3.56 per share in cash and one CVR, providing a defined exit value and potential future upside.
• Option Holders (e.g., Scott M Whitcup): Those with in-the-money options received cash and CVRs, while those with out-of-the-money options had them cancelled for no consideration, aligning with typical merger terms.
• Adverum Biotechnologies, Inc. as an entity: Transitioned from a publicly traded company to a wholly-owned subsidiary of Eli Lilly and Company, impacting its operational autonomy and strategic direction.

Next Steps

• Eli Lilly and Company will integrate Adverum Biotechnologies, Inc. as a wholly-owned subsidiary.
• Computershare Inc. and Computershare Trust Company, N.A. will act as rights agent for the contingent value rights (CVRs).
• Future contingent cash payments to CVR holders will be made upon the achievement of specified milestones.

Key Dates

Keywords

Adverum Biotechnologies, ADVM, Eli Lilly and Company, Merger, Acquisition, Stock Options, Contingent Value Right, CVR, Insider Transaction, Beneficial Ownership, Form 4